0.7301
Scynexis Inc stock is traded at $0.7301, with a volume of 59,679.
It is down -1.07% in the last 24 hours and down -2.52% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$0.738
Open:
$0.73
24h Volume:
59,679
Relative Volume:
0.39
Market Cap:
$28.49M
Revenue:
$135.87M
Net Income/Loss:
$72.20M
P/E Ratio:
0.5142
EPS:
1.42
Net Cash Flow:
$45.09M
1W Performance:
+0.70%
1M Performance:
-2.52%
6M Performance:
-31.77%
1Y Performance:
-64.98%
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SCYX
Scynexis Inc
|
0.7301 | 28.80M | 135.87M | 72.20M | 45.09M | 1.42 |
![]()
ZTS
Zoetis Inc
|
152.12 | 68.04B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.48 | 46.30B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.88 | 44.25B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.54 | 18.73B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
304.50 | 13.82B | 2.99B | 1.21B | 1.13B | 25.06 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-22-21 | Initiated | Guggenheim | Buy |
Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
Jul-11-18 | Upgrade | Needham | Hold → Buy |
Jun-27-18 | Initiated | Maxim Group | Buy |
Oct-24-17 | Initiated | Guggenheim | Buy |
Jul-10-17 | Initiated | ROTH Capital | Buy |
May-09-17 | Downgrade | Needham | Buy → Hold |
Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
Oct-20-16 | Initiated | H.C. Wainwright | Buy |
Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
Oct-03-16 | Resumed | Brean Capital | Buy |
Aug-17-16 | Initiated | Guggenheim | Buy |
Aug-09-16 | Reiterated | Needham | Buy |
Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
Mar-28-16 | Initiated | Brean Capital | Buy |
Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
Jun-10-15 | Initiated | Needham | Buy |
May-29-14 | Initiated | Canaccord Genuity | Buy |
May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
Is SCYNEXIS Inc. a good long term investmentTremendous growth opportunities - Autocar Professional
What drives SCYNEXIS Inc. stock priceFastest return on investment - Autocar Professional
What analysts say about SCYNEXIS Inc. stockUnstoppable profit momentum - Autocar Professional
SCYNEXIS Inc. Stock Analysis and ForecastFast-track wealth growth - Autocar Professional
Is ATH.PRA a good long term investmentSkyrocketing returns - Jammu Links News
What makes SCYNEXIS Inc. stock price move sharplyTop Analyst Picks - Newser
Why SCYNEXIS Inc. stock attracts strong analyst attentionGrowth Stock Monitor - Newser
How SCYNEXIS Inc. stock performs during market volatilityFree Stock Market Analysis Courses - Newser
Scynexis Inc (SCYX) Stock: A Year of Highs and Lows in the Market - investchronicle.com
SCYNEXIS Holds Annual Meeting, Re-elects Directors - The Globe and Mail
SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price - TipRanks
Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World
Biosergen taps antifungal expert as board member - Biostock
Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN
SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey
Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks
SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus
GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus
SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):